The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

R. Malekzadeh | T. Vos | M. Naghavi | H. Suleria | S. Hay | Fares Alahdab | T. Meretoja | Ali Bijani | A. Daryani | D. Davițoiu | Gebre Teklemariam Demoz | M. Dirac | F. Farzadfar | F. Fischer | A. Gebre | S. Hamidi | M. K. Hole | S. Irvani | S. James | A. Kengne | E. Khan | R. Kimokoti | A. Koyanagi | Ana-Laura Manda | Varshil Mehta | T. Meštrović | E. Mirrakhimov | A. Mokdad | G. Moradi | G. Mustafa | I. Negoi | H. Nguyen | M. Nixon | A. Pourshams | H. Poustchi | A. Rafiei | D. Rawaf | S. Rawaf | Nicholas Roberts | G. Roshandel | S. Safiri | H. Salimzadeh | B. Sartorius | S. Sepanlou | B. Tran | Derrick Tsoi | K. Vosoughi | A. Werdecker | M. Zamani | R. Adedoyin | U. Bacha | M. Banach | D. Colombara | H. Do | C. Nguyen | U. Ghoshal | S. Amini | Milad Mohammadoo-khorasani | Saeed Safari | A. Mohammadian-Hafshejani | A. Biondi | Kevin S Ikuta | A. Bhagavathula | A. Kabir | C. L. Hoang | K. Corey | M. Vacante | T. Kavetskyy | A. Soheili | N. Rabiee | M. Moossavi | P. Mithra | P. Vahedi | Y. Veisani | B. Thakur | S. Nasseri-Moghaddam | J. Nazari | M. Rabiee | Baye Dagnew | Feleke Mekonnen Demeke | A. Ghashghaee | Milad Hasankhani | A. Khater | Solomon Olum | Abdulaziz M. Almulhim | Shoaib Hassan | F. Joukar | Maseer Khan | M. D. Naimzada | A. Sarveazad | D. Tadesse | F. G. Tela | Y. Yeshitila | Kaleab Alemayehu Zewdie | A. Borzì | A. Etemadi | F. Ausloos | Zhi-Jiang Zhang | D. Mehta | Rovshan Khalilov | B. E. Tesfay | Adam Wondmieneh | Amrollah Sharifi | Berhe Gebremichael | Narjes Akhlaghi | O S Ilesanmi | A. Afshin | Hadush Gebremariam | Hagazi Gebremedhin Kassaye | Muhammad U Khan | Kevin S. Ikuta | K. Ikuta | C. Nguyen | Siavosh Nasseri-Moghaddam | D. B. Tadesse

[1]  Deepak L. Bhatt,et al.  Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. , 2019, Gastroenterology.

[2]  Chien-Chang Lee,et al.  Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta‐analysis of randomized controlled trials and observational studies , 2019, Expert opinion on drug safety.

[3]  N. Dubey,et al.  Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis , 2018, European journal of gastroenterology & hepatology.

[4]  Madhu Sudhan Atteraya,et al.  Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[5]  Mohammad Hosein Farzaei,et al.  Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[6]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[7]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[8]  Reza Ghadimi.  Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[9]  Haniye Sadat Sajadi,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[10]  Dan J Stein,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[11]  J. Rubenstein,et al.  Presentation and Epidemiology of Gastroesophageal Reflux Disease. , 2017, Gastroenterology.

[12]  C. Miller,et al.  Laparoscopic Reoperative Antireflux Surgery Is More Cost-Effective than Open Approach. , 2017, Journal of the American College of Surgeons.

[13]  T. Vos,et al.  Global, regional, and national incidence and prevalence, and years lived with disability for 328 diseases and injuries in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017 .

[14]  Eyal Oren,et al.  Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015 , 2017, The Lancet.

[15]  P. Moayyedi,et al.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults. , 2017, The Cochrane database of systematic reviews.

[16]  F. Bazzoli,et al.  Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis , 2017, Gut.

[17]  G. Triadafilopoulos,et al.  Budget Impact Analysis to Estimate the Cost Dynamics of Treating Refractory Gastroesophageal Reflux Disease With Radiofrequency Energy: a Payer Perspective. , 2016, Managed care.

[18]  H. El‐Serag,et al.  Lifestyle Intervention in Gastroesophageal Reflux Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  Mirjam Kretzschmar,et al.  Disability weights for the Global Burden of Disease 2013 study. , 2015, The Lancet. Global health.

[20]  J. Lam,et al.  Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis , 2015, PloS one.

[21]  T. Vos,et al.  Assessing disability weights based on the responses of 30,660 people from four European countries , 2015, Population Health Metrics.

[22]  A. Smout,et al.  Systematic review: questionnaires for assessment of gastroesophageal reflux disease. , 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[23]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[24]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[25]  N. Freedman,et al.  Gastroesophageal Reflux in Relation to Adenocarcinomas of the Esophagus: A Pooled Analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) , 2014, PloS one.

[26]  R. Malekzadeh,et al.  Gastroesophageal Reflux Disease and overall and Cause-specific Mortality: A Prospective Study of 50000 Individuals. , 2014, Middle East journal of digestive diseases.

[27]  Christopher C Winchester,et al.  Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review , 2013, Gut.

[28]  Scott M Langevin,et al.  Gastric Reflux Is an Independent Risk Factor for Laryngopharyngeal Carcinoma , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[29]  M. Vela,et al.  Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease , 2013, The American Journal of Gastroenterology.

[30]  Alan D. Lopez,et al.  Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[31]  P. Wahlqvist,et al.  Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA , 2012, Pragmatic and observational research.

[32]  Andrew T Chan,et al.  Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study , 2012, BMJ : British Medical Journal.

[33]  G. Leontiadis,et al.  Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies , 2011, The American Journal of Gastroenterology.

[34]  A. Kasaeian,et al.  Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study. , 2011, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[35]  D. Bauer,et al.  Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. , 2011, The American journal of medicine.

[36]  Y. Loke,et al.  Meta-analysis: risk of fractures with acid-suppressing medication. , 2011, Bone.

[37]  Sang Min Park,et al.  Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.

[38]  D. Whiteman,et al.  Esophageal Adenocarcinoma Incidence in Individuals With Gastroesophageal Reflux: Synthesis and Estimates From Population Studies , 2011, The American Journal of Gastroenterology.

[39]  J. Dent,et al.  Systematic review: ageing and gastro‐oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis , 2011, Alimentary pharmacology & therapeutics.

[40]  J. Rubenstein,et al.  Meta-Analyses of the Effect of Symptoms of Gastroesophageal Reflux on the Risk of Barrett's Esophagus , 2010, The American Journal of Gastroenterology.

[41]  R. Fedorak,et al.  Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[42]  C. Shin,et al.  Comparison of Direct Medical Care Costs Between Erosive Reflux Disease and Non-erosive Reflux Disease in Korean Tertiary Medical Center , 2010, Journal of neurogastroenterology and motility.

[43]  A. Barkun,et al.  Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. , 2010, The American journal of medicine.

[44]  M. Weiner,et al.  Gastro-oesophageal acid-related disease, co-morbidity and medical care cost , 2008, Chronic illness.

[45]  R. Malekzadeh,et al.  Prospective Acid Reflux Study of Iran (PARSI): Methodology and study design , 2007, BMC gastroenterology.

[46]  H. El‐Serag,et al.  The association between gastro-oesophageal reflux disease and asthma: a systematic review , 2007, Gut.

[47]  D. Corley,et al.  Body Mass Index and Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis , 2006, The American Journal of Gastroenterology.

[48]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[49]  Seth D. Crockett,et al.  Are Lifestyle Measures Effective in Patients With Gastroesophageal Reflux Disease?: An Evidence-Based Approach , 2006 .

[50]  A. Raghunath,et al.  Beyond heartburn: a systematic review of the extra-oesophageal spectrum of reflux-induced disease. , 2005, Family practice.

[51]  H. El‐Serag,et al.  Meta-Analysis: Obesity and the Risk for Gastroesophageal Reflux Disease and Its Complications , 2005, Annals of Internal Medicine.

[52]  J. Dent,et al.  Epidemiology of gastro-oesophageal reflux disease: a systematic review , 2005, Gut.

[53]  M. Mínguez,et al.  Dental and periodontal lesions in patients with gastro-oesophageal reflux disease. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[54]  Jan J Barendregt,et al.  A generic model for the assessment of disease epidemiology: the computational basis of DisMod II , 2003, Population health metrics.

[55]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[56]  Rafael Lozano,et al.  AGE STANDARDIZATION OF RATES: A NEW WHO STANDARD , 2000 .